Short answer
CVRx, Inc. (CVRX) filed an 8-K current report with the SEC on April 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 provides no earnings figures or operating results in the supplied text.
CVRx, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 provides no earnings figures or operating results in the supplied text
- Language is a standard SEC non-incorporation disclaimer, not substantive financial disclosure
Item 8.01 · Other Events
- Q1 2026 preliminary revenue $14.7–$14.8M, approximately 20% growth from $12.3M
- Gross margin expected at 87%, up from 84%; operating expenses approximately $25M versus $23.7M
- Medicare Advantage 30-day authorization rate reached 50% in early 2026, up from 31% in 2024
- Cash and equivalents approximately $72.3M; active U.S. implanting centers increased to 257
- BENEFIT-HF first site activated; potential indication expansion approximately three times if trial succeeds
Item EX-99.1 · Exhibit EX-99.1
- Preliminary Q1 revenue $14.7M–$14.8M, approximately 20% growth versus $12.3M in Q1 2025
- Gross margin expected at approximately 87%, up from 84% year over year
- Medicare Advantage 30-day prior-authorization approval rate reached 50% in early 2026, versus 44% in 2025
- 257 U.S. implanting centers and 56 sales territories, supporting broader Barostim commercial reach
- BENEFIT-HF trial first site activated; success could expand Barostim’s indicated population approximately three times
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CVRx, Inc. 8-K filings
Get the next CVRX 8-K as it lands
Follow CVRX for push alerts, or ask the research agent what this filing means.